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Introduction: Although continuous regional arterial infusion (CRAI) of a protease inhibitor and an antibiotic may be
effective in patients with severe acute pancreatitis, CRAI has not yet been validated in large patient populations. We
therefore evaluated the effectiveness of CRAI based on data from a national administrative database covering 1,032
Japanese hospitals.
Methods: In-hospital mortality, length of stay and costs were compared in the CRAI and non-CRAI groups, using
propensity score analysis to adjust for treatment selection bias.
Results: A total of 17,415 eligible patients with acute pancreatitis were identified between 1 July and 30 September
2011, including 287 (1.6%) patients who underwent CRAI. One-to-one propensity-score matching generated 207
pairs with well-balanced baseline characteristics. In-hospital mortality rates were similar in the CRAI and non-CRAI
groups (7.7% vs. 8.7%; odds ratio, 0.88; 95% confidence interval, 0.44–1.78, P = 0.720). CRAI was associated with
significantly longer median hospital stay (29 vs. 18 days, P < 0.001), significantly higher median total cost (21,800 vs.
12,600 United States dollars, P < 0.001), and a higher rate of interventions for infectious complications, such as
endoscopic/surgical necrosectomy or percutaneous drainage (2.9% vs. 0.5%, P = 0.061).
Conclusions: CRAI was not effective in reducing in-hospital mortality rate in patients with acute pancreatitis, but
was associated with longer hospital stay and higher costs. Randomized controlled trials in large numbers of patients
are required to further evaluate CRAI for this indication.Introduction
Acute pancreatitis is an inflammatory disease of the pan-
creas with a wide spectrum of severity. It is character-
ized by autodigestion of the pancreas due to activation
of inherent proteases and frequently involves surround-
ing retroperitoneal tissues and/or remote organ systems.
Although recent advances in intensive care and aggres-
sive treatment methods specialized for acute pancreatitis
[1,2] have dramatically reduced the mortality rate associ-
ated with this condition, mortality due to severe nec-
rotizing pancreatitis is not uncommon [3,4]. Protease
inhibitors may directly suppress pancreatic inflammation* Correspondence: isayama-tky@umin.ac.jp
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reproduction in any medium, provided the orby inhibiting pancreatic enzymes and improving coagulop-
athy [5,6]. In addition, antibiotics have been reported to re-
duce the mortality associated with severe acute pancreatitis
by preventing secondary infection of the necrotic pancre-
atic tissue [7,8], although its effectiveness on mild acute
pancreatitis has not been demonstrated [3]. In acute necro-
tizing pancreatitis, however, pancreatic ischemia due to
vasospasm and enhanced intravascular coagulation inhibit
protease inhibitors and prevent intravenously administered
antibiotics from penetrating into pancreatic tissue.
Continuous regional arterial infusion (CRAI), rather
than systemic intravenous administration, may be a the-
oretically reasonable drug delivery system for patients
with severe acute pancreatitis. Administration of a prote-
ase inhibitor through a catheter placed into one of the
arteries supplying the inflamed pancreas can dramatic-
ally increase the effective concentration of this agent inl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spective, uncontrolled case series have suggested that
CRAI may reduce mortality associated with acute necro-
tizing pancreatitis [11-15]. To the best of our knowledge,
however, only one randomized controlled trial has
assessed mortality rates in patients administered a prote-
ase inhibitor and an antibiotic via CRAI [16]. In that
study, which involved 78 patients with severe acute pan-
creatitis, the mortality rate was significantly lower in the
CRAI group than in the non-CRAI group (5.1% vs. 23.1%;
P = 0.02). Owing to the small sample size and lack of
stratification, however, the characteristics of patients in
the CRAI and non-CRAI groups were poorly balanced,
with the CRAI group being younger and having a better
computed tomography (CT) severity index, possibly lead-
ing to an overestimation of the efficacy of CRAI [17].
Thus, the effectiveness of CRAI for acute necrotizing pan-
creatitis remains unclear.
We therefore evaluated the effectiveness of CRAI of a
protease inhibitor and an antibiotic in patients with
acute pancreatitis by performing a one-to-one propensity
score–matched analysis of patients with or without CRAI
derived from a nationwide administrative database of in-
patient care in Japan.
Materials and methods
Data source
The Diagnosis Procedure Combination (DPC) database
is an original case mix administrative database of inpa-
tients in Japan that provides data on admission and dis-
charge abstracts as well as administrative claims. The
DPC system has been adopted by acute care hospitals in
Japan [18,19]. Data on approximately seven million inpa-
tients hospitalized between 1 July 2010 and 30 June 2011
were collected from more than 1,000 hospitals throughout
Japan, representing approximately 50% of all acute care
hospitalizations during the same period in Japan. The main
diagnoses, comorbidities present at admission and compli-
cations during hospitalization were recorded using the
International Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10) codes and text data in
the Japanese language. The database also contains detailed
medical information, such as patients’ age and sex; length
of hospital stay; discharge status, including in-hospital
death; unique identifiers of the hospitals; types of hospitals
(academic and nonacademic); interventional and surgical
procedures; medications and devices indexed by the ori-
ginal codes in Japanese; and cost data. The database also
includes consciousness status at the time of admission and
discharge based on the Japan Coma Scale (JCS), in which a
score of 0 indicates alert consciousness, scores of 1 to 3
indicate wakefulness without any stimuli, scores of 10 to
30 indicate arousal by some stimuli and scores of 100 to
300 indicate coma. The JCS and the Glasgow Coma Scaleassessments are well-correlated [20,21]. Each patient with a
principal diagnosis of acute pancreatitis was given the high-
est prognostic factor and CT severity index scores within
48 hours of admission according to the Japanese severity
scoring system by the attending physicians [22,23].
This study was approved by the institutional review
board of The University of Tokyo Hospital, which waived
the requirement for patient informed consent because of
the anonymous nature of the data.
Japanese severity scoring system for acute pancreatitis
The severity of acute pancreatitis was determined for each
patient on the basis of the Japanese severity score (prog-
nostic factor score) determined by summing nine factors,
along with the CT severity score [22,24]. Table 1 shows
the details of this scoring system. Severe acute pancreatitis
was diagnosed when the total prognostic factor score was
3 or higher or the CT severity grade was 2 or higher [22].
Continuous regional arterial infusion of a protease
inhibitor and an antibiotic
CRAI consisted of the continuous infusion of a protease
inhibitor and an antibiotic (usually carbapenem) through
a catheter inserted into one of the arteries perfusing the
inflamed lesion of the pancreas. The general methods of
CRAI were as follows. The catheter used for CRAI was
the same as the one used for angiography. Following CT
evaluation of the hypoenhanced area of the pancreas,
angiography of the pancreas was performed. The catheter
tip was located in the artery perfusing the area containing
the main lesion of hypoperfusion of the pancreas. If the
main lesion was located in the head of the pancreas, the
catheter tip was placed in the common hepatic, gastroduo-
denal or superior mesenteric artery; if the main lesion was
located in the body or tail of the pancreas, the catheter tip
was placed in the celiac, splenic or dorsal pancreatic artery;
and if the lesion involved the entire pancreas, the catheter
tip was placed in the celiac artery. CRAI was usually
started within 2 or 3 days of admission.
Patient selection and data
We identified all adult patients (20 years of age or older)
who were admitted to the participating hospitals with a
principal diagnosis of acute pancreatitis (ICD-10 code
K85) and were discharged between 1 July 2010 and 30
September 2011. Patients transferred within 7 days of
hospitalization were excluded because transfer was based
on Japanese guidelines recommending that patients with
a prognostic factor score of 3 or higher be transferred
to a specialized medical institution [22]. Patients who
underwent CRAI for acute pancreatitis were identified
based on the performance of selective arterial angiog-
raphy combined with the infusion of a protease inhi-
bitor (gabexate mesilate or nafamostat mesilate) and a
Table 1 Japanese severity scoring system for acute pancreatitis of the Ministry of Health, Labour and Welfare of Japan
(2008 revision)a
Scoring system Basis for score
Prognostic factor score (one point for
each factor)
1 Base excess less than or equal to −3 mEq/L or shock (systolic blood pressure below 80 mmHg)
2 PaO2 ≤60 mmHg (room air) or respiratory failure (respiratory assistance needed)
3 BUN ≥40 mg/dl or (or creatinine ≥2.0 mg/dl) or oliguria (daily urine output <400 ml even after
intravenous fluid resuscitation)
4 LDH at or above twice the upper limit of normal
5 Platelet count ≤100,000/mm3
6 Serum calcium ≤7.5 mg/dl
7 CRP ≥15 mg/dl
8 Number of positive measures in SIRS criteria ≥3
9 Age ≥70 years
CT grade based on contrast-enhanced CT
1 Extrapancreatic progression of inflammation
Anterior pararenal space, zero points
Root of mesocolon, one point
Beyond lower pole of kidney, two points
2 Hypoenhanced lesion of the pancreas
Pancreas conveniently divided into three segments (head, body and tail).
Localized in each segment or surrounding only the pancreas, zero points
Extends to two segments, one point
Occupies two whole segments or more, two points
Factors 1 + 2 = total score
Total score = 0 or 1, grade 1
Total score = 2, grade 2
Total score = 3 or more, grade 3
Assessment of severity If prognostic factor score is ≥3 or CT grade is ≥2, acute pancreatitis is considered severe.
aBUN, Blood urea nitrogen; CRP, C-reactive protein; CT, Computed tomography; LDH, Lactate dehydrogenase; PaO2, partial pressure of oxygen in blood; SIRS, Systemic
inflammatory response syndrome. Measures within the SIRS criteria include body temperature above 38°C or less than 36°C, heart rate more than 90 beats/min, respiratory
rate more than 20 breaths/min or partial pressure of carbon dioxide in blood less than 32 torr, as well as white blood cell count above 12,000 cells/mm3,
less than 4,000 cells/mm3 or greater than 10% immature (band) forms. The 2008 revision of the Japanese severity scoring system is contained in [22].
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nem, biapenem or panipenem). The cohort for propensity
score analysis was generated by combining those patients
who underwent CRAI within 3 days of admission and pa-
tients who had intravenous infusions with both a protease
inhibitor and a carbapenem antibiotic within 3 days of ad-
mission. The types of protease inhibitors and antibiotics
initially administered via CRAI were also recorded.
The baseline characteristics, prognostic factor scores and
CT severity scores at the time of admission of each patient
were recorded. JCS [20,21] was categorized into four
groups: 0, 1 to 3, 10 to 30 and 100 to 300. Comorbidities,
assessed by recording ICD-10 codes, were converted into
scores, and these scores were summed to calculate the
Charlson comorbidity index (CCI) score for each patient
based on Quan’s algorithm [25]. Hospital volume wasdefined as the number of inpatients with acute pancreatitis
per year per hospital and was categorized into quartiles
(very low, low, high and very high volume) containing ap-
proximately equal numbers of patients [26]. Hospital type
was categorized as academic or nonacademic.
Outcomes
The primary outcome of this study was in-hospital mor-
tality. Secondary outcomes included length of hospital
stay, total costs and requirement of intervention for
infectious complications, that is, endoscopic or surgical
necrosectomy or percutaneous drainage.
Statistical analyses
A retrospective observational design was utilized to
evaluate the effectiveness of CRAI of a protease inhibitor
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likely to be performed in more severely ill patients, an
unadjusted comparison of CRAI and non-CRAI groups
may be subject to treatment selection bias [27,28], re-
sulting in an underestimation of the effectiveness of
CRAI. To overcome this bias, we performed a propen-
sity score analysis [27,28]. A propensity score was calcu-
lated for each patient in the cohort as described, using
a logistic regression model with baseline variables that
potentially influenced the selection of CRAI, including
age, sex, JCS score, CCI score, prognostic factor score,
CT severity index score, hospital volume and hospital
type. We then matched patients in the CRAI patient
cohort one-to-one with patients in the non-CRAI group
by propensity score matching using the estimated pro-
pensity scores of each patient based on the nearest neigh-
bor method within a caliper. In this algorithm, each
patient in the non-CRAI group was matched with a
patient in the CRAI group with the closest estimated
propensity score within a specified range (≤0.25 of
the pooled standard deviation of estimated propensity
scores) [29]. C-statistics were used to evaluate goodness
of fit.
Continuous variables were described as means and
standard deviations or medians and interquartile ranges
(IQRs) and were compared using Student’s t-test or the
Mann–Whitney U test as appropriate. Between-group
differences in categorical variables were compared using
Fisher’s exact test or a χ2 test as appropriate. The trend
toward higher in-hospital mortality with later admin-
istration of CRAI was evaluated using the Cochrane-
Armitage trend test. A multivariate logistic regression
model was used to compare in-hospital mortality in
the CRAI and non-CRAI groups, with adjustment of
propensity score quintiles.
The Cochrane-Armitage trend test was performed using
R software version 2.15.1 (R Development Core Team;
http://www.r-project.org). All other statistical analyses were
performed using IBM SPSS Statistics version 19 software
(IBM, Armonk, NY, USA). P < 0.05 was considered statisti-
cally significant.
Results
Patient selection and matching
During the 15-month study period, 21,468 patients ages
20 years and older were hospitalized with acute pancrea-
titis at the 1,032 DPC participating hospitals (116 aca-
demic and 916 nonacademic hospitals). We identified
17,415 patients whose prognostic factor scores and CT se-
verity scores upon admission were both recorded and who
had not been transferred within 7 days of hospitalization.
From among these 17,415 patients, 287 (1.6%) underwent
CRAI at 29 academic and 70 nonacademic hospitals. The
cohort used for propensity score analysis consisted of 247patients who underwent CRAI within 3 days of admission
(the CRAI group) and 1,307 patients who underwent
intravenous administration of a protease inhibitor and
a carbapenem antibiotic within 3 days of admission (the
non-CRAI group).
Patients in the CRAI and non-CRAI groups had mean
propensity scores of 0.334 (95% confidence interval
(CI) = 0.308 to 0.360) and 0.126 (95% CI = 0.119 to 0.133),
respectively. The C-statistic (area under the receiver oper-
ating characteristic curve) was 0.811. Using the algorithm
described above, we were able to match 207 patients in the
CRAI group with 207 in the non-CRAI group (Figure 1).
Patient characteristics
The characteristics of all patients in the CRAI and non-
CRAI groups (n = 1,554) and in the 207 propensity-
matched pairs (n = 414) are shown in Table 2. Analysis
of the total patient population showed that patients in
the CRAI group was younger and more likely to be
treated in academic hospitals, and they had higher prog-
nostic factor and CT severity index scores. CRAI was ad-
ministered on day 1 of admission to 109 patients (52.7%),
on day 2 to 60 patients (29.0%), on day 3 to 31 patients
(15.0%) and on day 4 to 7 patients (3.4%).
Propensity score matching revealed that patient char-
acteristics were similar in the adjusted CRAI and non-
CRAI groups. In particular, the CT severity scores did
not differ significantly between groups.
The protease inhibitors gabexate mesilate and nafamo-
stat mesilate were administered to 60.4% and 39.6%, re-
spectively, of the patients in the propensity-matched
CRAI group, and to 58.9% and 41.1%, respectively, of
the patients in the propensity-matched non-CRAI group.
The antibiotics meropenem, imipenem and others were
administered to 44.0%, 43.0% and 13.0%, respectively, of
the patients in the propensity-matched CRAI group, and
to 60.9%, 32.9% and 6.2%, respectively, of the patients in
the propensity-matched non-CRAI group.
Outcomes in the CRAI and non-CRAI groups
Among all 1,554 eligible patients, the in-hospital mortal-
ity rate was higher in the CRAI group than in the non-
CRAI group (8.5% vs. 6.8%; P = 0.342). Outcomes in the
propensity-matched CRAI and non-CRAI groups are sum-
marized in Table 3. In-hospital mortality rates were similar
(7.7% vs. 8.7%, odds ratio (OR) = 0.88, 95% CI = 0.44 to
1.78; P = 0.720). In-hospital mortality rates were 4.6%
in patients who underwent CRAI on admission day 1,
10.0% on day 2 and 13.2% on day 3 or later. Earlier ad-
ministration of CRAI tended to be associated with
lower in-hospital morality rate (P = 0.064). In addition,
length of hospital stay was significantly longer (P < 0.001)
and total costs during hospitalization were significantly
higher (P < 0.001) in the matched CRAI group than in
Figure 1 Flowchart of patients with acute pancreatitis and propensity matching of patients with or without continuous regional
arterial infusion. CRAI, Continuous regional arterial infusion; CT, Computed tomography.
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ventions for infectious complications tended to be higher
in the matched CRAI group (2.9% vs. 0.5%; P = 0.061). In
detail, four patients in the matched CRAI group and one
in the matched non-CRAI group required endoscopic
necrosectomy, and two patients in the matched CRAI
group required percutaneous drainage. No patient re-
quired surgical necrosectomy.
Logistic regression analysis with adjustment for pro-
pensity score quintiles showed that the in-hospital
mortality rate (adjusted OR = 0.88; 95% CI = 0.43 to
1.78; P = 0.711) and the rate of interventions for infec-
tious complications (adjusted OR = 6.42, 95% CI = 0.75
to 54.6; P = 0.089) were similar in the matched CRAI
and non-CRAI groups (Table 4). Linear regression ana-
lysis with adjustment for the same variables as those
used in the calculation of propensity scores showed
that hospital stay was 16.5 days longer (P < 0.001) and cost
was US$13,600 higher (P < 0.001) in the matched CRAI
cohort than in the matched non-CRAI group (Table 4).
Discussion
To more accurately evaluate CRAI of a protease inhibi-
tor and an antibiotic in patients with acute pancreatitis,
we performed propensity score analysis based on large-
scale data from the Japanese nationwide administrative
database. We found that CRAI was ineffective in that it
did not reduce the in-hospital mortality rate, but rather
was associated with an increased rate of interventions for
infectious complications associated with acute pancreatitis.
In addition, CRAI was associated with significantly longer
hospital stays and significantly higher total costs.Several small retrospective studies have suggested that
CRAI may be effective in patients with severe acute pan-
creatitis [11-15]. To date, only one randomized controlled
trial has shown that CRAI reduced mortality rates, but
that study was limited by its relatively small sample size
(78 patients) [16]. CRAI was originally performed in pa-
tients with pancreatic necrosis caused by acute pancrea-
titis, a condition with a high mortality rate. This treatment
selection bias has hindered a simple retrospective com-
parison evaluating the efficacy of CRAI; that is, patients
who underwent CRAI were likely to be at greater risk of
acute pancreatitis-associated mortality, thus leading to
underestimation of the efficacy of CRAI. The younger age
of our CRAI cohort relative to our non-CRAI group was
likely to enhance outcomes in the former [30], whereas
the higher prognostic factor and CT severity index scores
in the CRAI group would likely have a negative effect on
outcomes [31]. Thus, to control for baseline prognostic
heterogeneity and inherent treatment selection biases, we
performed propensity score analysis [27,28]. We found
that one-to-one propensity score matching resulted in
a successful balance of baseline characteristics, includ-
ing CT severity score, the factor that usually determines
whether CRAI is administered.
When we compared the propensity-matched groups,
we found that, in contrast to previous studies, in-hospital
mortality rates were similar between our CRAI and non-
CRAI groups, despite the tendency of earlier administra-
tion of CRAI to be associated with a lower in-hospital
mortality rate. Although we expected that CRAI of an
antibiotic would result in a lower rate of infectious com-
plications, we found that the rate of requirement for





PPatient characteristics CRAI (n = 247) Non-CRAI (n = 1,307) CRAI (n = 207) Non-CRAI (n = 207)
Mean age (years) 54.6 ± 16.4 60.6 ± 18.1 <0.001 56.7 ± 16.3 56.0 ± 17.6 0.684
Sex
Males 69.2% 67.6% 0.622 69.6% 66.7% 0.527
Females 30.8% 32.4% 30.4% 33.3%
CCI score
0 47.4% 43.1% 0.404 48.8% 48.3% 0.944
1 or 2 41.7% 46.2% 42.5% 42.0%
≥ 3 10.9% 10.7% 8.7% 9.7%
JCS score
0 89.9% 94.3% 0.407 90.8% 92.3% 0.711
1 to 3 6.9% 4.5% 6.8% 5.8%
10 to 30 2.0% 0.8% 1.4% 0.5%
100 to 300 1.2% 0.4% 1.0% 1.4%
Prognostic factor score
0 29.1% 48.3% <0.001 34.3% 35.3% 0.970
1 12.6% 24.3% 14.0% 14.5%
2 17.4% 11.1% 18.4% 15.0%
3 20.2% 7.8% 16.9% 16.9%
4 12.1% 3.6% 8.2% 8.2%
5 2.4% 2.3% 2.4% 2.4%
≥ 6 6.1% 2.7% 5.8% 7.7%
CT severity score
0 13.4% 47.8% <0.001 15.9% 15.5% 0.999
1 9.3% 20.4% 11.1% 10.6%
2 38.9% 21.7% 42.0% 43.0%
3 23.9% 6.0% 18.4% 18.8%
4 14.6% 4.1% 12.6% 12.1%
Hospital volume (per 12 months)
≤ 14 21.5% 20.0% 0.324 21.7% 24.6% 0.835
15 to 22 21.1% 26.3% 22.2% 23.7%
23 to 32 24.3% 24.3% 23.7% 21.3%
≥ 33 33.2% 29.4% 32.4% 30.4%
Hospital type
Academic 31.2% 21.3% 0.001 28.0% 24.6% 0.435
Community 68.8% 78.7% 72.0% 75.4%
aAge shown as mean and standard deviation. Prognostic factor score and CT severity score were based on the Japanese severity scoring system for acute
pancreatitis (2008 revision) [22]. CCI, Charlson comorbidity index; CRAI, Continuous regional arterial infusion; CT, Computed tomography; JCS, Japan Coma Scale.
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group. In addition, hospital stay was significantly longer
and total costs were significantly higher in the CRAI co-
hort than in the non-CRAI group.
This study has several limitations. First, it was not a
prospective, randomized controlled trial, but rather wasbased on a retrospective design. Although we performed
propensity score analysis to overcome this limitation,
several biases may remain because of unobserved con-
founders. For example, the criteria for and timing of ad-
ministration of CRAI were not predefined, and the
changes in the prognostic factor and CT severity scores
Table 3 Outcomes in the propensity-matched continuous regional arterial infusion and non–continuous regional
arterial infusion groupsa
Outcomes CRAI (n = 207) Non-CRAI (n = 207) P
In-hospital mortality, n (%) 16 (7.7%) 18 (8.7%) 0.720
Median length of stay, days (IQR) 28.5 (18.3 to 36.8) 18.0 (12.0 to 28.0) <0.001
Median cost, US$ (IQR) $21,800 ($16,200 to $32,400) $12,600 ($7,940 to $21,700) <0.001
Interventions for infectious complications, n (%) 6 (2.9%) 1 (0.5%) 0.061
aCRAI, Continuous regional arterial infusion; IQR, Interquartile range.
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the condition of some patients diagnosed with “non-
severe” acute pancreatitis upon admission may have wors-
ened rapidly, thus unfavorably affecting the outcomes in
our CRAI group. Second, CT severity score was de-
termined by scoring and summing two independent fac-
tors: extrapancreatic progression of inflammation and
hypoenhanced lesions of the pancreas. These two factors
affect the efficacy of CRAI differently, although total
CT severity scores were well-balanced in our adjusted
CRAI and non-CRAI groups. Third, the unavailability of
some important clinical data from the DPC database may
have affected patient outcomes, including the etiologies
of acute pancreatitis [32,33], symptoms of sepsis, data
on organ failure, dosages of protease inhibitors and anti-
biotics on a daily basis and detailed results of blood tests
and CT. The information on readmissions and outpatient
visits was also unavailable, which inhibited the analysis
of late mortality associated with acute pancreatitis. The
multiplicity of protease inhibitors and antibiotics used
constitutes another limitation.
Despite these limitations, a major strength of this study
was the evaluation of CRAI for acute pancreatitis in a large
number of patients with well-balanced baseline charac-
teristics, including prognostic factor score affecting in-
hospital mortality rate, such as age [30], sex [32,34],
consciousness [30], prognostic factor score [31] and CT
severity score. To the best of our knowledge, this study is
the largest to date that has evaluated CRAI, and it in-
cluded patients who underwent CRAI in a large number
of hospitals (n = 99), including 70 nonacademic hospitalsTable 4 Odds ratios for in-hospital mortality and intervention
of stay and cost of the CRAI group, compared with the non-C
Variable Odds ratio
In-hospital mortality 0.88
Interventions for infectious complications 6.42
Length of stay (days)
Cost (US dollars)
The odds ratios were calculated using logistic regression analysis with adjustment f
analysis with adjustment for age, sex, JCS, CCI, prognostic factor score, CT score, howith a relatively low hospital volume and 29 academic
hospitals, thus providing internal validity. Because of
its invasiveness and cost, CRAI should not routinely be
performed in patients with acute pancreatitis until its
efficacy has been well-established and its indications are
confirmed.
Conclusions
On the basis of our propensity score analysis of large-
scale data from a nationwide administrative database, we
found that CRAI was not effective in the treatment of
acute pancreatitis and that it cost more. Well-designed,
randomized controlled trials including large numbers of
patients are needed to further evaluate the efficacy of
this procedure.
Key messages
 Because little is known about the potential
effectiveness of CRAI in patients with severe acute
pancreatitis, the effectiveness and costs of CRAI
were evaluated on the basis of data derived from a
nationwide, large-scale database.
 One-to-one propensity score matching was
performed to adjust for treatment selection bias,
and 207 well-balanced pairs were compared.
 CRAI failed to demonstrate superiority regarding
mortality rate, length of hospital stay and total
cost, suggesting the need for large randomized
controlled trials to further evaluate the
effectiveness of CRAI.s for infectious complications and coefficients for length
RAI group
CRAI vs. non-CRAI
Coefficient 95% CI P
0.43 to 1.78 0.711
0.75 to 54.6 0.089
16.5 11.8 to 21.2 <0.001
$13,600 6,890 to 20,400 <0.001
or propensity score quintiles, and the coefficients using linear regression
spital volume and hospital type.
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